Open company graph database — free web & API
Login

Shukokai Medical Corporation

医療法人社団 珠光会医療法人社団珠光会Alias
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
33
§01

Basic information

BASIC
Head office
Chief executive
Capital
Employees (non-consolidated)
Employees (consolidated)
Start date
1958-01-01
End date
§02

Websites

1 DOMAINS
§03

Business

8
Cancer prevention and treatmentImmunotherapyDendritic cell therapyCell therapyPalliative careOperation of Seigaoka HospitalOperation of the long-term care health facility Hijiri no SatoEstablishment of the Hasumi Regenerative Medicine Research Institute and HASUMI Immunotherapy Clinic, and cancer treatment
§04

Related companies

33 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
GICC
HASUMI免疫クリニック
Hasumi International Research Foundation
ICVS東京クリニック
エアランゲン大学
オーストリア・アカデミー・オブ・サイエンス
ニューヨーク科学アカデミー
プレーヴェン大学
マレーシア国民大学付属病院
メリーランド大学
中国医学科学院癌研究所
中国長春中医学院
介護老人保健施設聖の郷
北京中医薬大学
北京珠光会
北京珠光会医薬品開発有限公司
医療法人社団ICVS
Bohui Biotechnology Co., Ltd.
吉林省腫瘍医院
Saitama Medical University
S.I.J. Co., Ltd.
珠光会インターナショナル
米国トーマス・ジェファーソン大学
米国メリーランド大学
米国国立癌研究所
米国法人蓮見国際研究財団
聖ヶ丘病院
英国王立医学会
英屬開曼群島商雅智有限公司台灣分公司
蓝莲(杭州)生物科技有限公司
蓮見再生医療研究所
蓮見国際研究財団ブルガリア
蓮見癌研究所
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

65 EVENTS

The late Dr. Kiichiro Hasumi conceived the viral theory of cancer and began vaccine research.Sources

Established the Hasumi Cancer Research Institute in Chofu, TokyoSources

Successfully isolated a virus from a cervical cancer patient using ionized ceramicsSources

Began the clinical application of the Hasumi VaccineSources

Successfully isolated the equine infectious anemia virusSources

Established the Shukokai Medical CorporationSources

Opened the Shukokai ClinicSources

Began an experiment on cancer prevention using the Hasumi Vaccine in Heguri Village, Nara PrefectureSources

Began LAK therapySources

Since 1988, under the current leadership, efforts have focused on developing cancer antigen libraries for each type of cancer and expanding the range of cancers for which Hasumi Vaccine can be used.Sources

Kenichiro Hasumi became chairman of the boardSources

Seigaoka Hospital openedSources

Began publishing the Hasumi Cancer Research Institute's Research Reports annuallySources

Began research and clinical studies using dendritic cellsSources

Opened a hospice ward at Seigaoka Hospital, making it the fourth palliative care facility in TokyoSources

Established the U.S. corporation Hasumi International Research Foundation and developed a framework for cancer researchSources

Established Shukokai International in the United States and strengthened the framework for overseas research on the Hasumi VaccineSources

Began clinical research on the Hasumi Vaccine with the FIOCRUZ Institute of Brazil's Ministry of Health and the Fortaleza Claude Bernard Institute in BrazilSources

Established S.I.J. Co., Ltd. and established a cooperative relationship with the U.S. corporation Shukokai InternationalSources

In 1999, the Hasumi International Research Foundation was established in the United States. By deepening ties with researchers around the world, it conducts research and development on advanced cancer immunotherapies and their clinical applications.Sources

In 1999, a dendritic cell vaccine was developed through joint research with Thomas Jefferson University.Sources

In 2000, the bioactivity of Hasumi Vaccine was demonstrated through joint research with the University of Maryland.Sources

Began management improvements and introduced GMP/GLPSources

Introduced self-managed medical records at the Shukokai Clinic and promoted awareness of the importance of self-management of cancerSources

Demonstrated the adjuvant activity of the Hasumi Vaccine at the University of Maryland in the United StatesSources

The NPO Immunotherapy Roundtable was approved by the Tokyo Metropolitan Government.Sources

The Hasumi Cancer Research Institute developed the anti-cancer herbal medicine Immuno Hasumi and began clinical application (in cooperation with Saitama Medical University and Changchun University of Chinese Medicine, China).Sources

The Hasumi DC & AT vaccine was jointly developed with Thomas Jefferson University in the United States, and clinical trials began.Sources

Supported the first lecture hosted by the NPO Immunotherapy Roundtable, “Mechanisms of Cancer Recognition and Elimination,” featuring invited speaker Hiroyuki Itsuki (held in Osaka).Sources

A Phase I clinical trial began in Brazil.Sources

Supported the first International Cancer Vaccine Symposium (held in Tokyo), hosted by the Hasumi International Research Foundation, which was attended by many internationally active researchers.Sources

Juhokai International began research and development of supplements.Sources

Kenichiro Hasumi, Chairman of the Board, delivered an invited lecture at the 10th international conference “AIDS, Cancer and Related Problems” (held in St. Petersburg, Russia).Sources

The cancer vaccine book “Zero In On the Cancer Cell” was published by the U.S. corporation Hasumi International Research Foundation.Sources

A Cell Therapy Center was established.Sources

Beijing Juhokai Pharmaceutical Development Co., Ltd. was established and partnered with Beijing University of Chinese Medicine.Sources

The Hasumi Vaccine Friends Association was established.Sources

The “Centennial Celebration of the Birth of Dr. Kiichiro Hasumi” was held (hosted by Seirenkai).Sources

The 3rd International Cancer Vaccine Symposium (held in London) was jointly hosted by the U.S. corporation Hasumi International Research Foundation and the Royal Society of Medicine.Sources

IMUH Co., Ltd. was established to promote awareness and practice of specialized immune testing.Sources

In 2005, a prototype HITV (Human Initiated Therapeutic Vaccine) therapy was successfully developed as a “therapeutic vaccine” combining conventional treatments such as radiation therapy and chemotherapy with cell therapy using dendritic cells.Sources

A Shanghai Juhokai office was opened.Sources

Hijirigaoka Hospital received accreditation from the Japan Council for Quality Health Care.Sources

“Fighting Cancer with the Power of Immunity” was published by the U.S. corporation Hasumi International Research Foundation.Sources

A Phase I clinical trial of CD3-AT cell therapy began in Taiwan.Sources

The 4th International Cancer Vaccine Symposium (held in Washington, D.C.) was jointly hosted by the U.S. corporation Hasumi International Research Foundation and the U.S. National Cancer Institute.Sources

The first Tokyo lecture was held at the Tokyo Otemachi Sankei Plaza Hall, and has been held annually since then.Sources

Held a memorial ceremony commemorating the 15th anniversary of Seikaku Hospital.Sources

The 5th International Cancer Vaccine Symposium (in Vienna) was held in collaboration with the U.S. corporation Renmei International Research Foundation and the Austrian Academy of Sciences.Sources

Published by the U.S. corporation Renmei International Research Foundation: 'Cancer Vaccine of Love from a Determined Doctor to a Determined Patient Until the End.'Sources

Opened the ICVS Tokyo Clinic, affiliated with the U.S. corporation Renmei International Research Foundation, as a dendritic cell therapy specialty facility.Sources

The 6th International Cancer Vaccine Symposium was co-hosted with the New York Science Academy.Sources

Chairman Renmei delivered an invited lecture at Murni Teghu Memorial Hospital, established in Medan, Indonesia, under the theme 'Future Cancer Treatment - New Concept and Modality.'Sources

In 2013, the research facility was relocated from Chofu to Asagaya, and an even more extensive research system was established.Sources

In 2013, development advanced on an “acne vaccine” intended to use the power of the immune system to eliminate acne bacteria, one of the causes of acne. The vaccine uses artificially synthesized antigen peptides based on membrane proteins of acne bacteria and has been patented in countries around the world.Sources

To unify the flow from cancer prevention to treatment, the Jukou Clinic was relocated and integrated into BSL-48 Clinic; the corporate headquarters office and Renmei Cancer Research Institute were also relocated.Sources

Following the research and clinical achievements of cancer vaccines by the late Dr. Kiichiro Renmei, which received high acclaim, the first Japanese physician in the history of American medical universities was awarded a professorship at Thomas Jefferson University in the United States, bearing the name 'Renmei.'Sources

Opened K-101 Clinic, aiming to be a comprehensive clinic centered on immunotherapy.Sources

In 2015, to comply with the Act on the Safety of Regenerative Medicine, an application was filed to register the clean room at the research institute as a cell culture and processing facility. Following an on-site inspection by the Pharmaceuticals and Medical Devices Agency (PMDA), authorization was obtained to manufacture specified processed cells (facility number: FA3150018).Sources

Topic: “A Medical Roadmap to Avoid Getting Lost in Cancer Treatment” Speaker: Kenichiro Hasumi, Chairman of the Hasumi International Research Foundation, a U.S. corporationSources

Topic: “Immunotherapy’s Evolution—What Is Happening Now at the Front Lines of Cancer Treatment, and What Will Happen Next?” Speaker: Kenichiro Hasumi, Chairman of the Hasumi International Research Foundation, a U.S. corporationSources

BSL-48 Clinic relocated to Asagaya and was renamed BSL-48 Jukou Clinic. K-101 Clinic was renamed BSL-48 International Clinic and moved to the former BSL-48 Clinic location.Sources

Topic: “Stage IV Cancer Treatment: A New Perspective” Speaker: Kenichiro Hasumi, Chairman of the Hasumi International Research Foundation, a U.S. corporationSources

BSL-48 Jukou Clinic and BSL-48 International Clinic merged, and HASUMI Immunology Clinic opened.Sources

Renmei Cancer Research Institute was renamed Renmei Regenerative Medicine Research Institute.Sources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑